COMPARE · Data as of August 24, 2026
NBIX vs VTRS
Verdict: Side-by-side breakdown using the Bull Rankings model. NBIX scored 88.1, VTRS scored 50.1 — NBIX leads.
Compare another set
NBIX
Neurocrine Biosciences, Inc.
88.1
$153.04 · $15.6B
fundamentals as of
Score gap
38.0
NBIX leads
VTRS
Viatris Inc.
50.1
$16.54 · $19.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthNBIX+34.4%
- Strongest balance sheetNBIX0.12
- Highest qualityNBIX81 / 100
- Largest discount to fair valueVTRS-44%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
NBIX
stronger →← stronger
VTRS
81
Qualityreturns · margins · balance sheet
38
96
Growthrevenue & earnings expansion
42
88
Valuevaluation vs sector peers
77
NBIX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
NBIX
VTRS
$870mC+
FCF
$2.0bC+
+34.4%A
Rev
+4.5%C+
0.12B+
D/E
0.96C
22.3xB+
P/E
—
0.45A
PEG
1.05B+
—
P/S
1.3xA-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
NBIX
VTRS
11% below
Price vs fair valuelower is cheaper
44% below
~8%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-9%/yr
-6%
1-yr DCF upside
+71%
+12%
5-yr DCF upside
+80%
+46%
10-yr DCF upside
+93%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
NBIX
Why this score
- Durable high returns
- Diluting shareholders
VTRS
The companies
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.6b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.45 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $211.57 (implying +38% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
VTRSViatris Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $19.0b. 10% off the 52-week high of $18.39. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $18.50 (implying +12% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -23.9%) — path to GAAP profitability is the core thesis risk. ROE -25% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where NBIX and VTRS diverge
On the headline score the gap is 38.0 points in favor of NBIX. The widest single difference is Growth, where NBIX leads by 53.6 points.
- GrowthNBIX 95.9 · VTRS 42.3NBIX +53.6
- QualityNBIX 81.1 · VTRS 38.4NBIX +42.7
- ValueNBIX 88.0 · VTRS 77.5NBIX +10.5
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.